Episodios

  • Managing Acute Exacerbations in Fibrotic Interstitial Lung Disease in the Hospitalized Patient

    Managing Acute Exacerbations in Fibrotic Interstitial Lung Disease in the Hospitalized Patient
    Mar 11 2026
    In this episode of Hospital Medicine Unplugged, we sprint through acute exacerbation of interstitial lung disease (AE-ILD)—recognize the sudden decline, rule out infection and cardiac causes, support oxygenation, and navigate a disease with limited treatment options and high mortality. We begin with the diagnostic framework defined by the 2016 International Working Group. Acute exacerbation is characterized by rapid respiratory deterioration within about 1 month, accompanied by new bilateral ground-glass opacities or consolidation on CT superimposed on pre-existing fibrotic lung disease, with no evidence of cardiac failure or fluid overload. Importantly, this definition now applies across fibrosing interstitial lung diseases, not just idiopathic pulmonary fibrosis (IPF). The critical bedside principle: AE-ILD is a diagnosis of exclusion. Infection, pulmonary embolism, pneumothorax, and heart failure must be aggressively ruled out because they can mimic exacerbations and require completely different management. Next, we turn to pathobiology and why these patients deteriorate so rapidly. Acute exacerbations often represent diffuse alveolar damage superimposed on chronic fibrosis, producing a clinical picture similar to ARDS. However, in some non-IPF ILDs, organizing pneumonia patterns are more common—one reason those patients may respond better to immunosuppressive therapy. Treatment remains challenging because no therapy has definitively proven benefit in randomized trials. Corticosteroids remain the most widely used intervention, but evidence is mixed. Recent data suggest a key difference between ILD subtypes. In non-IPF ILD, higher-dose corticosteroids (>1 mg/kg prednisone equivalent) have been associated with improved survival and lower 90-day mortality. Early tapering—reducing doses by more than 10% within the first two weeks—may further improve outcomes. In contrast, IPF exacerbations respond less predictably, and some studies suggest high-dose steroids may increase mortality, likely because the underlying pathology is often diffuse alveolar damage rather than steroid-responsive inflammation. One therapy that should not be used is cyclophosphamide combined with steroids, which has been shown to increase mortality in acute exacerbations of IPF. Respiratory support becomes the next critical decision point. Many patients develop severe hypoxemic respiratory failure, but outcomes with invasive mechanical ventilation are poor. Across multiple studies: • In-hospital mortality ranges from 66–79% in ventilated ILD patients • Only ~20% of ventilated IPF patients survive to hospital discharge Ventilator management therefore focuses on lung-protective strategies, similar to ARDS care: • Low tidal volumes • Plateau pressures ≤30 cm H₂O • Avoid excessive PEEP, which has been associated with worse outcomes • Careful fluid management to prevent worsening pulmonary edema Because survival after intubation is so limited, early discussions about goals of care are essential. Noninvasive ventilation or high-flow nasal oxygen may be appropriate for selected patients who decline intubation. Prevention is therefore critically important. Antifibrotic therapies have significantly reduced exacerbation risk in IPF. Two major agents are used: • Nintedanib – shown in the INPULSIS trials to reduce the risk of acute exacerbations • Pirfenidone – also associated with lower exacerbation rates in multiple studies Meta-analyses show antifibrotics reduce the risk of acute exacerbations by roughly 37%, and nintedanib has also been approved for progressive fibrosing ILDs beyond IPF, after the INBUILD trial demonstrated substantial slowing of lung function decline. New therapies are also emerging. The FIBRONEER-ILD trial studied nerandomilast, a novel PDE-4 inhibitor, and although the composite endpoint did not reach statistical significance, the study demonstrated a meaningful reduction in mortality, suggesting a potential future role in progressive pulmonary fibrosis. Another key strategy is early referral for lung transplantation, particularly in patients with progressive fibrotic disease. Acute exacerbations can occur unpredictably and often represent a terminal event in advanced ILD, making transplant evaluation crucial before severe deterioration occurs. We close with the key system moves for inpatient teams: • Recognize sudden respiratory decline in patients with fibrotic lung disease • Confirm new bilateral ground-glass opacities on CT • Aggressively rule out infection, pulmonary embolism, and heart failure • Consider corticosteroids, particularly in non-IPF ILD • Use lung-protective ventilation if respiratory failure develops • Discuss prognosis early and involve palliative care • Ensure patients with fibrotic ILD are on antifibrotic therapy when appropriate Acute exacerbation of ILD remains one of the most devastating events in pulmonary medicine—but early recognition, careful ...
    Más Menos
    45 m
  • Status Epilepticus Evidence-Based Management and Escalation Algorithms for the Hospitalist

    Status Epilepticus Evidence-Based Management and Escalation Algorithms for the Hospitalist
    Mar 9 2026
    In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in. We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes. The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury. Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses. Three effective options: • IV lorazepam 0.1 mg/kg (max 4 mg), may repeat once • IM midazolam 10 mg (0.3 mg/kg in children) — preferred if IV access unavailable • IV diazepam 0.15 mg/kg, may repeat once The biggest real-world mistake isn’t drug choice—it’s delay and underdosing. If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice. The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients. Recommended doses: • Levetiracetam 60 mg/kg (max 4500 mg) • Fosphenytoin 20 mg PE/kg • Valproate 40 mg/kg Because efficacy is equivalent, patient factors guide the choice: • Cardiac disease → avoid fosphenytoin (hypotension/arrhythmia risk) • Pregnancy or liver disease → avoid valproate • Simplest safety profile → levetiracetam Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used. When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring. Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity: • Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use • Midazolam infusion — commonly used but tachyphylaxis develops • Pentobarbital coma — powerful seizure suppression but high rates of hypotension and prolonged sedation Most modern practice favors propofol or midazolam over barbiturate coma. A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease. If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%. Management expands to include: • Ketamine infusions • Immunotherapy (steroids, IVIG, plasmapheresis) when autoimmune etiologies are suspected • Ketogenic diet • Neuromodulation or epilepsy surgery in select cases Two particularly challenging syndromes fall into this category: NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome), often requiring aggressive immunologic treatment. Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome. Prognosis varies dramatically depending on response to therapy: • Benzodiazepine-responsive SE: <5% mortality • Second-line responsive SE: ~10–15% mortality • Refractory SE: 20–40% mortality • Super-refractory SE: up to 50% mortality Poor outcomes are associated with older age, acute symptomatic etiologies (stroke, infection, hypoxic injury), prolonged seizures, and nonconvulsive status epilepticus with coma, which is one of the strongest predictors of mortality. Finally, systems matter. Hospitals that implement structured status epilepticus protocols dramatically improve outcomes. Protocol adherence reduces time to second-line therapy from nearly an hour to about 20 minutes and lowers ICU transfer rates. We close with the practical escalation algorithm every inpatient team should know: • 0–5 minutes: ABCs, glucose check, IV access, prepare meds • 5–10 minutes: benzodiazepine (lorazepam, midazolam, or diazepam) • 10–20 minutes: second-line AED (levetiracetam, fosphenytoin, or valproate) • 20–40 minutes: prepare for intubation, initiate EEG monitoring • Refractory SE: ...
    Más Menos
    44 m